Showing 31-40 of 1354 results for "".
In-Focus: Alzheimer's Disease
https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/in-focus-alzheimers-disease/30347/- Therapeutics Q&Ahttps://practicalneurology.com/columns/practice-management/therapeutics-qa/31184/Integrating Antidepressant Therapy in Parkinson’s Disease ManagementDepression is a common comorbidity in Parkinson’s disease (PD) patients, necessitating careful consideration for antidepressant therapy. Dr. Eric J. Ahlskog, a leading neurologist at the Mayo Clinic, emphasizes the interplay between
- Can We Boost The Efficacy of Dopaminergic Therapy?https://practicalneurology.com/columns/practice-management/can-we-boost-the-efficacy-of-dopaminergic-therapy/31220/Parkinson’s disease (PD) management continues to prioritize maintaining patients' quality of life and motor function, aligning with the foundational goals established since Dr. James Parkinson’s initial descriptions in 1817. Contemporary treatment primarily focuses on dopamine replacement to counter
Update on Noninvasive Neuromodulation Devices for Headache Treatment
https://practicalneurology.com/diseases-diagnoses/headache-pain/update-on-noninvasive-neuromodulation-devices-for-headache-treatment/31283/Stewart J. Tepper, MD, Vice President of the New England Institute for Neurology and Headache, Peter McAllister, MD, FAAN, Chief Medical Officer of the New England Institute for Neurology and Headache, and Teshamae Monteith, MD, Associate Professor and Chief of the Headache Division of the DepartmenLevodopa 2.0: New Strategies to Even Out the Peaks and Valleys
https://practicalneurology.com/diseases-diagnoses/movement-disorders/levodopa-20-new-strategies-to-even-out-the-peaks-and-valleys/30552/An update on the newest pharmacologic options to manage symptoms of PD.Alpha-Synuclein: A Therapeutic Target and Potential Biomarker in Parkinson's Disease
https://practicalneurology.com/diseases-diagnoses/movement-disorders/alpha-synuclein-a-therapeutic-target-and-potential-biomarker-in-parkinsons-disease/30407/- Therapeutics Q&Ahttps://practicalneurology.com/columns/practice-management/therapeutics-qa/31129/Pharmacological Management of Myasthenia Gravis in Young Adults Versus Older PatientsManaging myasthenia gravis (MG) requires tailored pharmacological strategies, especially when comparing young adults to older individuals with similar disease severity. Experts Dr. Henry J. Kaminski and Dr. Zohar Ar
Knocking Out PD Symptoms?
https://practicalneurology.com/diseases-diagnoses/movement-disorders/knocking-out-pd-symptoms/30659/Exercise is crucial for patients with Parkinson's. One program wants to give them a fighting chance.Convention Question: What Will Drive the Next Great Advance in Stroke Treatment?
https://practicalneurology.com/diseases-diagnoses/stroke/convention-question-what-will-drive-the-next-great-advance-in-stroke-treatment/30121/Answers from attendees of the International Stroke Conference in Honolulu, HI, Feb 6th-8th, 2019.Raising Urate With Inosine to Potentially Slow Progression of Parkinson's Disease
https://practicalneurology.com/diseases-diagnoses/movement-disorders/movement-disorders-focus/30688/Results of the Phase II SURE-PD study show inosine is safe and tolerable and raises urate levels, which have been inversely related to Parkinson's progression. Still, patients are cautioned against self-medicating before the next phase of this research effort is completed.